RxDoctor Payments Data

Sujata Holman, MD

Cardiovascular Disease · Springfield, MANPI 1104085505

Payments from drug & device makers

$2,858in general payments, 2019–2025

Across 146 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$809
  • Pfizer$585
  • AstraZeneca$250
  • Boehringer Ingelheim$171
  • Alnylam Pharmaceuticals Inc.$145
  • E.r. Squibb & Sons, L.L.C.$133
  • plus $764 from 17 others

What the payments were for

  • Food & beverage$2,858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,858 in reported general payments places this provider in the 55th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$155,699
Medicare patients
999
Services billed
2,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban376$414,757
EntrestoSacubitril/Valsartan190$236,303
FarxigaDapagliflozin Propanediol76$91,772
XareltoRivaroxaban69$78,492
JardianceEmpagliflozin40$57,475
Repatha SureclickEvolocumab47$41,307
Repatha SyringeEvolocumab29$28,690
MultaqDronedarone Hcl13$21,645
Praluent PenAlirocumab23$17,216
BrilintaTicagrelor26$12,293
Metoprolol Succinate361$8,077
Rosuvastatin Calcium168$6,410
Atorvastatin Calcium261$4,261
Ezetimibe63$3,935
Isosorbide Mononitrate ErIsosorbide Mononitrate151$3,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$585$414,757376 claims
NovartisEntresto$809$236,303190 claims
AstraZenecaFarxiga, Brilinta$250$104,064102 claims
Johnson & JohnsonXarelto$86$78,49269 claims
Boehringer IngelheimJardiance$171$57,47540 claims
Sanofi-aventis U.S. LLCMultaq$21$21,64513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →